
    
      The trial consists of two parallel arms to study the therapeutic success of 48 weeks,
      tolerability, immunological recovery, persistence of treatment, safety and results reported
      by the subject in severely immunocompromised HIV infected patients (with an initial CD4 count
      <200 cells/Î¼l) naive to antiretroviral therapy.

      Included subjects will be randomized two to one (2:1) to RAL 1200mg QD plus FTC/TAF or DRV/cb
      (800-150mg) plus FTC/TAF.
    
  